FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559672196> ?p ?o ?g. }

• W2559672196 abstract "Abstract Background: It has been suggested that using an acute lymphoblastic leukemia (ALL) rather than non-Hodgkin lymphoma protocol to treat patients with lymphoblastic lymphoma (LL) might be associated with better results (Hoelzer, Best Pract Res Clin Haematol 2002). To address this issue, the GRAALL and LYSA groups have conducted the Phase 2 LL03 trial in adult patients with LL, using the GRAALL-2003 protocol, which yielded good results in adult patients with ALL (Huguet, JCO 2009). Patients and Methods: Between 2004 and 2012, 155 patients aged 18-59 years were enrolled, including 131 evaluable patients with T-cell LL (T-LL). The pediatric-inspired ALL treatment included a corticosteroid prephase, a 5-drug induction with sequential cyclophosphamide, high dose consolidation, late intensification, CNS prophylaxis with IT injections and cranial irradiation, and a 2-year maintenance. Response, including complete remission (CR) and unconfirmed CR (CRu), were assessed using Cheson criteria (Cheson, JCO 1999). Allogeneic stem cell transplantation (SCT) was offered to CR/CRu patients with high-risk disease (defined as need for a second-induction salvage course and/or CNS disease) and a donor. Results: Of 131 T-LL patients (median age, 33 years; M/F ratio 4.0; mediastinal enlargement, 95%; CNS involvement, 5%), 119 patients (91%) reached CR/CRu (30 patients needing a salvage course) and 34 relapsed. Response evaluation was based on CT scan, as PET scan was performed in only 73/131 and 20/30 patients after first induction and salvage, respectively. At 5 years, estimated DFS, EFS and overall survival were 71%, 61% and 66%, respectively. The lymphoma IPI-score had no prognostic value, but increased serum LDH level (observed in 71% of the patients) was associated with a significant decrease in EFS (HR = 2.8 [1.3 – 6.1]) and OS (HR = 3.5 [1.4 – 9.1]) in multivariable analysis. Of note, need for a salvage course was not associated with shorter DFS in CR/CRu patients. In a subset of 49 patients studied for oncogenetic markers, the 4-gene risk classifier (based on NOTCH1, FBXW7, N/K-RAS and PTEN status) we have recently reported to be a powerful predictor in T-ALL patients (Trinquand, JCO 2013) also demonstrated strong prognostic value in T-LL. Among these patients, 29 (60%) had a high-risk genetic profile (defined as no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN deletion). At 3 years, the high-risk genetic profile was predictive of shorter EFS (HR = 14.3 [1.9 – 107.8]), DFS (HR = 9.5 [1.2 – 74.3]) and OS (HR = 11.5 [1.5 – 87.5]) in univariable analysis, as well as in multivariable analysis after adjustment on age, ECOG-PS and LDH level (HR = 20.5 [2.6 – 164.1], 12.6 [1.5 – 104.8] and 17.0 [2.1 – 136.8], respectively. A total of 30 CR/CRu patients were eligible for allogeneic SCT (25 for late CR/CRu, 4 for CNS involvement, and 1 for both criteria) and 17 of them were actually transplanted in first CR/CRu. When analysed as a time-dependent event, allogeneic SCT was not associated with prolonged DFS in these high-risk patients. Finally, Grade III/IV adverse events were those commonly observed with the GRAALL regimen. Overall, 46 patients died during the study (37 after relapse or progression; 5 during induction; 3 from allograft toxicity and 1 after a highway accident). Conclusion: As compared to historical studies, we report here a relatively good outcome in T-LL patients treated with a pediatric-inspired ALL strategy. Very interestingly, the NOTCH1/FBXW7/RAS/PTEN T-ALL risk classification was also a strong prognostic factor in these T-LL patients. Allogeneic SCT did not appear to significantly influence the outcome of selected T-LL patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2559672196 created "2016-12-08" @default.
• W2559672196 creator A5000436961 @default.
• W2559672196 creator A5004066423 @default.
• W2559672196 creator A5006682547 @default.
• W2559672196 creator A5018514641 @default.
• W2559672196 creator A5022075377 @default.
• W2559672196 creator A5026307215 @default.
• W2559672196 creator A5033236092 @default.
• W2559672196 creator A5036207495 @default.
• W2559672196 creator A5037324033 @default.
• W2559672196 creator A5043136683 @default.
• W2559672196 creator A5045374333 @default.
• W2559672196 creator A5045965285 @default.
• W2559672196 creator A5046761978 @default.
• W2559672196 creator A5047053152 @default.
• W2559672196 creator A5052144370 @default.
• W2559672196 creator A5052452447 @default.
• W2559672196 creator A5057563040 @default.
• W2559672196 creator A5064103067 @default.
• W2559672196 creator A5068303471 @default.
• W2559672196 creator A5071962621 @default.
• W2559672196 creator A5083855576 @default.
• W2559672196 creator A5086354986 @default.
• W2559672196 creator A5088148467 @default.
• W2559672196 date "2014-12-06" @default.
• W2559672196 modified "2023-10-04" @default.
• W2559672196 title "Pediatric ALL-like Therapy in Adults with T-Cell Lymphoblastic Lymphoma: Results of the Graall-Lysa LL03 Study" @default.
• W2559672196 doi "https://doi.org/10.1182/blood.v124.21.371.371" @default.
• W2559672196 hasPublicationYear "2014" @default.
• W2559672196 type Work @default.
• W2559672196 sameAs 2559672196 @default.
• W2559672196 citedByCount "1" @default.
• W2559672196 crossrefType "journal-article" @default.
• W2559672196 hasAuthorship W2559672196A5000436961 @default.
• W2559672196 hasAuthorship W2559672196A5004066423 @default.
• W2559672196 hasAuthorship W2559672196A5006682547 @default.
• W2559672196 hasAuthorship W2559672196A5018514641 @default.
• W2559672196 hasAuthorship W2559672196A5022075377 @default.
• W2559672196 hasAuthorship W2559672196A5026307215 @default.
• W2559672196 hasAuthorship W2559672196A5033236092 @default.
• W2559672196 hasAuthorship W2559672196A5036207495 @default.
• W2559672196 hasAuthorship W2559672196A5037324033 @default.
• W2559672196 hasAuthorship W2559672196A5043136683 @default.
• W2559672196 hasAuthorship W2559672196A5045374333 @default.
• W2559672196 hasAuthorship W2559672196A5045965285 @default.
• W2559672196 hasAuthorship W2559672196A5046761978 @default.
• W2559672196 hasAuthorship W2559672196A5047053152 @default.
• W2559672196 hasAuthorship W2559672196A5052144370 @default.
• W2559672196 hasAuthorship W2559672196A5052452447 @default.
• W2559672196 hasAuthorship W2559672196A5057563040 @default.
• W2559672196 hasAuthorship W2559672196A5064103067 @default.
• W2559672196 hasAuthorship W2559672196A5068303471 @default.
• W2559672196 hasAuthorship W2559672196A5071962621 @default.
• W2559672196 hasAuthorship W2559672196A5083855576 @default.
• W2559672196 hasAuthorship W2559672196A5086354986 @default.
• W2559672196 hasAuthorship W2559672196A5088148467 @default.
• W2559672196 hasConcept C126322002 @default.
• W2559672196 hasConcept C141071460 @default.
• W2559672196 hasConcept C2776694085 @default.
• W2559672196 hasConcept C2779338263 @default.
• W2559672196 hasConcept C2780775027 @default.
• W2559672196 hasConcept C2911091166 @default.
• W2559672196 hasConcept C71924100 @default.
• W2559672196 hasConcept C90924648 @default.
• W2559672196 hasConceptScore W2559672196C126322002 @default.
• W2559672196 hasConceptScore W2559672196C141071460 @default.
• W2559672196 hasConceptScore W2559672196C2776694085 @default.
• W2559672196 hasConceptScore W2559672196C2779338263 @default.
• W2559672196 hasConceptScore W2559672196C2780775027 @default.
• W2559672196 hasConceptScore W2559672196C2911091166 @default.
• W2559672196 hasConceptScore W2559672196C71924100 @default.
• W2559672196 hasConceptScore W2559672196C90924648 @default.
• W2559672196 hasLocation W25596721961 @default.
• W2559672196 hasOpenAccess W2559672196 @default.
• W2559672196 hasPrimaryLocation W25596721961 @default.
• W2559672196 hasRelatedWork W2395971691 @default.
• W2559672196 hasRelatedWork W2470563138 @default.
• W2559672196 hasRelatedWork W2523114003 @default.
• W2559672196 hasRelatedWork W2536855729 @default.
• W2559672196 hasRelatedWork W2537623059 @default.
• W2559672196 hasRelatedWork W2548097557 @default.
• W2559672196 hasRelatedWork W2556675457 @default.
• W2559672196 hasRelatedWork W2557679935 @default.
• W2559672196 hasRelatedWork W2557825309 @default.
• W2559672196 hasRelatedWork W2558853238 @default.
• W2559672196 hasRelatedWork W2559535493 @default.
• W2559672196 hasRelatedWork W2563166389 @default.
• W2559672196 hasRelatedWork W2566701295 @default.
• W2559672196 hasRelatedWork W2588142421 @default.
• W2559672196 hasRelatedWork W2590255442 @default.
• W2559672196 hasRelatedWork W2592551916 @default.
• W2559672196 hasRelatedWork W2913150948 @default.
• W2559672196 hasRelatedWork W2979454769 @default.
• W2559672196 hasRelatedWork W2982790839 @default.
• W2559672196 hasRelatedWork W984064889 @default.
• W2559672196 isParatext "false" @default.
• W2559672196 isRetracted "false" @default.
• W2559672196 magId "2559672196" @default.
• W2559672196 workType "article" @default.